Vanguard Asset Management
ORIC icon

Vanguard Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Vanguard Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Hold
25,189
– – ﹤0.01% 2341
2026
Q1 		$319K Buy
+25,189
New +$286K ﹤0.01% 2281

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIHC Capital Management Central $104M AUM
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

Vanguard Asset Management's ORIC Position: Q2 2026 in Review

Vanguard Asset Management held its Oric Pharmaceuticals (ORIC) position steady in Q2 2026 at 25,189 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

Vanguard Asset Management first reported a position in ORIC in Q1 2026 and has held it in 2 quarters since. The position peaked at $319K in Q1 2026. 163 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Vanguard Asset Management held 25,189 shares of Oric Pharmaceuticals worth $273K as of Q2 2026.
  • Vanguard Asset Management left its Oric Pharmaceuticals share count unchanged in Q2 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2341 holding.
  • Vanguard Asset Management first reported a position in Oric Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Oric Pharmaceuticals position peaked at $319K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.